[
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $64.49 as of April 15th. NVO’s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant […]",
    "url": "https://finnhub.io/api/news?id=8ebbc7aef4cd89beb7251c970ee5c1e9140e79ff8b6347437e5e4bbc87faa893",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744828655,
      "headline": "Novo Nordisk A/S (NVO): A Bull Case Theory",
      "id": 133942485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $64.49 as of April 15th. NVO’s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant […]",
      "url": "https://finnhub.io/api/news?id=8ebbc7aef4cd89beb7251c970ee5c1e9140e79ff8b6347437e5e4bbc87faa893"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9b645c5fd8c6923c565a3733437122f2701df75c29917d0249496447af9444e4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744821060,
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "id": 133945456,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9b645c5fd8c6923c565a3733437122f2701df75c29917d0249496447af9444e4"
    }
  },
  {
    "ts": null,
    "headline": "IYH: Healthcare Dashboard For April",
    "summary": "IYH: Healthcare Dashboard For April",
    "url": "https://finnhub.io/api/news?id=ef60e7fe50c851812342eddac8f56058cf17e7e5c0696e76992c679d592b9289",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744814463,
      "headline": "IYH: Healthcare Dashboard For April",
      "id": 133936894,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ef60e7fe50c851812342eddac8f56058cf17e7e5c0696e76992c679d592b9289"
    }
  },
  {
    "ts": null,
    "headline": "The GLP-1 drug shortage is over. What’s next for the compounders?",
    "summary": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
    "url": "https://finnhub.io/api/news?id=1809330ab10d34b75abdb2ef64fb78e70d8d82cca84af571019c6534342a85ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744814353,
      "headline": "The GLP-1 drug shortage is over. What’s next for the compounders?",
      "id": 133935605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
      "url": "https://finnhub.io/api/news?id=1809330ab10d34b75abdb2ef64fb78e70d8d82cca84af571019c6534342a85ff"
    }
  },
  {
    "ts": null,
    "headline": "Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)",
    "summary": "Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)",
    "url": "https://finnhub.io/api/news?id=699430856a9543401900d18a05229bb2ba87fe9f6763251f2f51a68b4c2c10b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744804123,
      "headline": "Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)",
      "id": 133935137,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=699430856a9543401900d18a05229bb2ba87fe9f6763251f2f51a68b4c2c10b9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?",
    "summary": "Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
    "url": "https://finnhub.io/api/news?id=8723f7c23c4adc71c780660f735200bef8efa1c466d2a58dba4e9db0dbb2a5fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744801500,
      "headline": "Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?",
      "id": 133935606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
      "url": "https://finnhub.io/api/news?id=8723f7c23c4adc71c780660f735200bef8efa1c466d2a58dba4e9db0dbb2a5fb"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'",
    "summary": "Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'",
    "url": "https://finnhub.io/api/news?id=ebf71246f6004e6d24ef934dd7967e8d868fc738dcb291a71d694308d19f8f7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744800975,
      "headline": "Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'",
      "id": 133934885,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ebf71246f6004e6d24ef934dd7967e8d868fc738dcb291a71d694308d19f8f7b"
    }
  },
  {
    "ts": null,
    "headline": "Analysis: Pharma companies expected to absorb any tariff hit in short term",
    "summary": "(Reuters) -U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs would likely be absorbed by drugmakers rather than patients whose payments are often set by health insurance.  U.S. health insurers, which pay the bulk of prescription drug costs, act as a buffer between drugmakers and patients, with beneficiaries subject to co-pays and co-insurance based on the prices insurers negotiate with drugmakers.  \"Patented drugs are already generally set at the price the market will bear, so in that sense manufacturers are not likely to substantially increase the prices of these drugs,\" said Melissa Barber, postdoctoral fellow at Yale University and an expert on drug pricing.",
    "url": "https://finnhub.io/api/news?id=1605564d3ee4d9c20fede5578d0c072dbd4851612b182a6bfc4f0de411fd85c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744797825,
      "headline": "Analysis: Pharma companies expected to absorb any tariff hit in short term",
      "id": 133935607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs would likely be absorbed by drugmakers rather than patients whose payments are often set by health insurance.  U.S. health insurers, which pay the bulk of prescription drug costs, act as a buffer between drugmakers and patients, with beneficiaries subject to co-pays and co-insurance based on the prices insurers negotiate with drugmakers.  \"Patented drugs are already generally set at the price the market will bear, so in that sense manufacturers are not likely to substantially increase the prices of these drugs,\" said Melissa Barber, postdoctoral fellow at Yale University and an expert on drug pricing.",
      "url": "https://finnhub.io/api/news?id=1605564d3ee4d9c20fede5578d0c072dbd4851612b182a6bfc4f0de411fd85c9"
    }
  }
]